NCT04100473View on ClinicalTrials.gov

Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 23, 2018

Primary Completion Date

August 11, 2018

Study Completion Date

August 1, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Inhaled Human Insulin

Dance 501 administered using the Dance 501 Inhaler

DRUG

Insulin Lispro (Humalog U-100)

Lispro

Trial Locations (1)

Unknown

Profil Mainz, Mainz

Sponsors
All Listed Sponsors
collaborator

Profil Institut für Stoffwechselforschung GmbH

INDUSTRY

lead

Dance Biopharm Inc.

INDUSTRY

NCT04100473 - Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter